Results from a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor, in Subjects with Advanced Solid Tumors or Recurrent Malignant Lymphoma

Tuesday, September 1, 2015   Posters and Presentations

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300